AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
hexamethonium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| quaternary ammonium compounds | 1366 | 60-26-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 58 | |||
| kinase-selectivity-class | AXL,BRAF,CAMK2A,CAMK2D,CDK4,EIF2AK3,EPHB4,FLT3,MAP3K7,MAP3K9,MAPK10,MAPK7,PLK1,PRKCD,PTK2,SIK2,STK33,TEK | 18 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000959 | Antihypertensive Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D005730 | Ganglionic Blockers |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018680 | Cholinergic Antagonists |
| MeSH PA | D018733 | Nicotinic Antagonists |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Neuronal acetylcholine receptor; alpha4/beta2 | Ion channel | IC50 | 4.54 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha4/beta4 | Ion channel | IC50 | 4.04 | CHEMBL | |||||
| Neuronal acetylcholine receptor subunit alpha-4 | Ion channel | BLOCKER | IC50 | 5.17 | IUPHAR | ||||
| Neuronal acetylcholine receptor subunit alpha-6 | Ion channel | BLOCKER | IC50 | 4.04 | IUPHAR | ||||
| Neuronal acetylcholine receptor; alpha4/beta2 | Ion channel | Ki | 4.66 | CHEMBL | |||||
| Acetylcholine receptor | Ion channel | Kd | 5.74 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D02204 | KEGG_DRUG |
| C0062637 | UMLSCUI |
| CHEBI:5700 | CHEBI |
| CHEMBL100622 | ChEMBL_ID |
| DB08960 | DRUGBANK_ID |
| CHEMBL2106122 | ChEMBL_ID |
| CHEMBL332524 | ChEMBL_ID |
| D018738 | MESH_DESCRIPTOR_UI |
| 3604 | PUBCHEM_CID |
| 3963 | IUPHAR_LIGAND_ID |
| 55-97-0 | SECONDARY_CAS_RN |
| 3C9PSP36Z2 | UNII |
| 001772 | NDDF |
| 004717 | NDDF |
| 49839002 | SNOMEDCT_US |
| 2047 | INN_ID |
Pharmaceutical products:
None